In this regard, primary heterotypic organoid cultures, stromally modified patient derived in vitro models and ‘organ on a chip’ approaches hold promise for deconvoluting CRIPTO function with relevant and interpretable yet sophisticated heterotypic signaling cells, key stromal effectors and tumor relevant modified environments that include cancer relevant stresses. This evidence concerns the gene CRIPTO and neoplasm.